{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:38:57Z","timestamp":1780591137664,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Xian Foundation for Development of Science and Technology, China","award":["20YXYJ0009(11)"],"award-info":[{"award-number":["20YXYJ0009(11)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11010-022-04390-8","type":"journal-article","created":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T04:02:26Z","timestamp":1649563346000},"page":"2015-2024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Monoclonal antibody Daratumumab promotes macrophage-mediated anti-myeloma phagocytic activity via engaging FC gamma receptor and activation of macrophages"],"prefix":"10.1007","volume":"477","author":[{"given":"Ying","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1003-3354","authenticated-orcid":false,"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,10]]},"reference":[{"issue":"1","key":"4390_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10\u201329. https:\/\/doi.org\/10.3322\/caac.20138","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"4390_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","volume":"8","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol. 8(8):479\u201391. https:\/\/doi.org\/10.1038\/nrclinonc.2011.63","journal-title":"Nat Rev Clin Oncol."},{"issue":"9","key":"4390_CR3","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1172\/JCI83871","volume":"125","author":"Y Yang","year":"2015","unstructured":"Yang Y (2015) Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 125(9):3335\u20133337. https:\/\/doi.org\/10.1172\/JCI83871","journal-title":"J Clin Invest"},{"key":"4390_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s11033-018-4427-x","volume":"373","author":"LM Weiner","year":"2009","unstructured":"Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373:1033\u20131040. https:\/\/doi.org\/10.1007\/s11033-018-4427-x","journal-title":"Lancet"},{"key":"4390_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278\u2013287. https:\/\/doi.org\/10.1038\/nrc3236","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4390_CR6","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186(3):1840\u20131848. https:\/\/doi.org\/10.4049\/jimmunol.1003032","journal-title":"J Immunol"},{"key":"4390_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV (2008) Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 8:34\u201347. https:\/\/doi.org\/10.1038\/nri2206","journal-title":"Nat Rev Immunol"},{"key":"4390_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","volume":"88","author":"A Veillette","year":"2013","unstructured":"Veillette A, Guo H (2013) CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 88:168\u2013177. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.04.003","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"4390_CR9","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3109\/10428194.2013.778409","volume":"54","author":"F Asimakopoulos","year":"2013","unstructured":"Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N, Hematti P (2013) Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma 54(10):2112\u20132121. https:\/\/doi.org\/10.3109\/10428194.2013.778409","journal-title":"Leuk Lymphoma"},{"key":"4390_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","volume":"7","author":"K Weiskopf","year":"2015","unstructured":"Weiskopf K, Weissman IL (2015) Macrophages are critical effectors of antibody therapies for cancer. MAbs 7:303\u2013310. https:\/\/doi.org\/10.1080\/19420862.2015.1011450","journal-title":"MAbs"},{"issue":"23","key":"4390_CR11","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-15-1330","volume":"75","author":"N G\u00fcl","year":"2015","unstructured":"G\u00fcl N, van Egmond M (2015) Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Can Res 75(23):5008\u20135013. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1330","journal-title":"Can Res"},{"issue":"9","key":"4390_CR12","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.4049\/jimmunol.1402891","volume":"194","author":"Y Shi","year":"2015","unstructured":"Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn M, Jordan RE, Strohl WR, Zou Q, Zhang N, An Z (2015) Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fc\u03b3 receptors on macrophages. J Immunol 194(9):4379\u20134386. https:\/\/doi.org\/10.4049\/jimmunol.1402891","journal-title":"J Immunol"},{"issue":"5","key":"4390_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5):699\u2013713. https:\/\/doi.org\/10.1016\/j.cell.2010.07.044","journal-title":"Cell"},{"issue":"2","key":"4390_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, Parren PW (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7(2):311\u2013321. https:\/\/doi.org\/10.1080\/19420862.2015.1007813","journal-title":"MAbs"},{"issue":"12","key":"4390_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","volume":"1","author":"NA Bezman","year":"2017","unstructured":"Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, Jenkins MR, Rogers AJ, Neeson PJ, Korman AJ, Robbins MD, Graziano RF (2017) PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Adv 1(12):753\u2013765. https:\/\/doi.org\/10.1182\/bloodadvances.2017004382","journal-title":"Blood Adv"},{"key":"4390_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","volume":"24","author":"MM Tomayko","year":"1989","unstructured":"Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148\u2013154. https:\/\/doi.org\/10.1007\/BF00300234","journal-title":"Cancer Chemother Pharmacol"},{"key":"4390_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-3-319-26666-4_12","volume":"899","author":"L Cassetta","year":"2016","unstructured":"Cassetta L, Noy R, Swierczak A, Sugano G, Smith H, Wiechmann L, Pollard JW (2016) Isolation of mouse and human tumor-associated macrophages. Adv Exp Med Biol 899:211\u2013229. https:\/\/doi.org\/10.1007\/978-3-319-26666-4_12","journal-title":"Adv Exp Med Biol"},{"issue":"28","key":"4390_CR18","doi-asserted-by":"publisher","first-page":"20119","DOI":"10.18632\/oncotarget.24614","volume":"9","author":"M Rossi","year":"2018","unstructured":"Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P (2018) Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget 9(28):20119\u201320133. https:\/\/doi.org\/10.18632\/oncotarget.24614","journal-title":"Oncotarget"},{"issue":"6","key":"4390_CR19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-15-2095","volume":"23","author":"A Matas-C\u00e9spedes","year":"2017","unstructured":"Matas-C\u00e9spedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Gin\u00e9 E, Roca-Ho H, Men\u00e9ndez P, Campo E, L\u00f3pez-Guillermo A, Colomer D, Rou\u00e9 G, Wiestner A, Parren PW, Doshi P, van Bueren JL, P\u00e9rez-Gal\u00e1n P (2017) The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia. Clin Cancer Res 23(6):1493\u20131505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2095","journal-title":"Clin Cancer Res"},{"key":"4390_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2172-14-6","volume":"14","author":"C Wang","year":"2013","unstructured":"Wang C, Yu X, Cao Q, Wang Y, Zheng G, Tan TK, Zhao H, Zhao Y, Wang Y, Harris DCh (2013) Characterization of murine macrophages from bone marrow, spleen and peritoneum. BMC Immunol 14:6. https:\/\/doi.org\/10.1186\/1471-2172-14-6","journal-title":"BMC Immunol"},{"key":"4390_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39\u201351. https:\/\/doi.org\/10.1016\/j.cell.2010.03.014","journal-title":"Cell"},{"issue":"5","key":"4390_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00277-012-1652-6","volume":"92","author":"E Suyan\u0131","year":"2013","unstructured":"Suyan\u0131 E, Sucak GT, Aky\u00fcrek N, Sahin S, Baysal NA, Ya\u011fc\u0131 M, Haznedar R (2013) Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol 92(5):669\u2013677. https:\/\/doi.org\/10.1007\/s00277-012-1652-6","journal-title":"Ann Hematol"},{"key":"4390_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ejh.12296","volume":"93","author":"MN Andersen","year":"2014","unstructured":"Andersen MN, Abildgaard N, Maniecki MB, M\u00f8ller HJ, Andersen NF (2014) Monocyte\/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol 93:41\u201347. https:\/\/doi.org\/10.1111\/ejh.12296","journal-title":"Eur J Haematol"},{"key":"4390_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49\u201361. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.010","journal-title":"Immunity"},{"issue":"18","key":"4390_CR25","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2016-01-695395","volume":"128","author":"A Guti\u00e9rrez-Gonz\u00e1lez","year":"2016","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez A, Mart\u00ednez-Moreno M, Samaniego R, Arellano-S\u00e1nchez N, Salinas-Mu\u00f1oz L, Relloso M, Valeri A, Mart\u00ednez-L\u00f3pez J, Corb\u00ed \u00c1L, Hidalgo A, Garc\u00eda-Pardo \u00c1, Teixid\u00f3 J, S\u00e1nchez-Mateos P (2016) Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood 128(18):2241\u20132252. https:\/\/doi.org\/10.1182\/blood-2016-01-695395","journal-title":"Blood"},{"issue":"9","key":"4390_CR26","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.celrep.2016.04.084","volume":"15","author":"AM Georgoudaki","year":"2016","unstructured":"Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, \u00d6stling J, Dahan R, Harris RA, Rantalainen M, Klevebring D, Sund M, Brage SE, Fuxe J, Rolny C, Li F, Ravetch JV, Karlsson MC (2016) Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep 15(9):2000\u20132011. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.084","journal-title":"Cell Rep"},{"key":"4390_CR27","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1158\/2326-6066.CIR-15-0025-T","volume":"8","author":"JL Jensen","year":"2015","unstructured":"Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F (2015) Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed\/Refractory Multiple Myeloma. Cancer Immunol Res 8:881\u2013890. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0025-T","journal-title":"Cancer Immunol Res"},{"key":"4390_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/icb.2016.121","volume":"95","author":"BC Barnhart","year":"2017","unstructured":"Barnhart BC, Quigley M (2017) Role of Fc\u2013FcgR interactions in the antitumor activity of therapeutic antibodies. Immunol Cell Biol 95:340\u2013346. https:\/\/doi.org\/10.1038\/icb.2016.121","journal-title":"Immunol Cell Biol"},{"issue":"11","key":"4390_CR29","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/leu.2009.130","volume":"23","author":"M Roussou","year":"2009","unstructured":"Roussou M, Tasidou A, Dimopoulos MA, Kastritis E, Migkou M, Christoulas D, Gavriatopoulou M, Zagouri F, Matsouka C, Anagnostou D, Terpos E (2009) Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 23(11):2177\u20132181. https:\/\/doi.org\/10.1038\/leu.2009.130","journal-title":"Leukemia"},{"issue":"4","key":"4390_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2015.03.004","volume":"27","author":"EF Zhu","year":"2015","unstructured":"Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, Dranoff G, Wittrup KD (2015) Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27(4):489\u2013501. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.004","journal-title":"Cancer Cell"},{"issue":"1","key":"4390_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","volume":"35","author":"D Viola","year":"2021","unstructured":"Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F (2021) Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia 35(1):189\u2013200. https:\/\/doi.org\/10.1038\/s41375-020-0810-4","journal-title":"Leukemia"},{"key":"4390_CR32","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X (2015) Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125:3384\u20133391. https:\/\/doi.org\/10.1172\/JCI80011","journal-title":"J Clin Invest"},{"issue":"8","key":"4390_CR33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793\u2013800. https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"issue":"127","key":"4390_CR34","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L (2012) Colocalization of inflammatory response with B7\u2013h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4(127):127ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3003689","journal-title":"Sci Transl Med."},{"issue":"Suppl 2","key":"4390_CR35","doi-asserted-by":"publisher","first-page":"P415","DOI":"10.1186\/2051-1426-3-S2-P415","volume":"3","author":"KA Schalper","year":"2015","unstructured":"Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Chen L, Sanmamed M, Herbst RS, Rimm DL (2015) Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer. J Immunother Cancer 3(Suppl 2):P415. https:\/\/doi.org\/10.1186\/2051-1426-3-S2-P415","journal-title":"J Immunother Cancer"},{"key":"4390_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb JR, Milne K, Kroeger DR, Nelson BH (2016) PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 141:293\u2013302. https:\/\/doi.org\/10.1016\/j.ygyno.2016.03.008","journal-title":"Gynecol Oncol"},{"key":"4390_CR37","doi-asserted-by":"publisher","first-page":"36956","DOI":"10.1038\/srep36956","volume":"6","author":"HR Kim","year":"2016","unstructured":"Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, Choi J, Cho BC, Yoon SO (2016) PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep 6:36956. https:\/\/doi.org\/10.1038\/srep36956","journal-title":"Sci Rep"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04390-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04390-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04390-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T12:36:04Z","timestamp":1656333364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04390-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,10]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4390"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04390-8","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,10]]},"assertion":[{"value":"27 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal protocols were approved by the animal ethical review committee of Shaanxi Provincial Peoples Hospital, China (approval number SP003V). The animal studies were in accordance to Guidelines for the ethical review of laboratory animal welfare People\u2019s Republic of China National Standard GB\/T 35892\u20132018 guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}